Wallace Max N. 4

What Happened

• Max N. Wallace, a director of Humacyte, Inc. (HUMA), received a grant of 80,000 derivative securities on June 11, 2026. The Form 4 reports the acquisition as an "A" award with a reported price of $0.00 and total reported value of $0 at grant. This is a compensation award (derivative security), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (timely filing).
• Security: 80,000 derivative shares (award/grant) reported at $0.00.
• Shares owned after transaction: not specified in the filing excerpt provided.
• Footnote: Vesting schedule — first 25% becomes exercisable on June 11, 2027; thereafter 1/48 vests monthly on the 11th through June 11, 2030.
• No 10b5-1 plan, tax-withholding sale, or late filing noted in the provided information.

Context

• The entry is a typical equity compensation grant for a director. As a derivative award with a multi-year vesting schedule, it does not represent an immediate purchase or sale and does not itself indicate intent to buy or sell shares in the open market. The economic value to the insider will depend on the award type (likely options or similar) and future stock price at vesting/exercise.